The advent of #immunotherapy has revolutionized the treatment algorithm in #NSCLC, with practice-changing implications for clinicians and their patients. In metastatic disease, an array of monotherapy and combination options offers unprecedented choices, enabling individualized approaches for each patient. However, unmet needs remain for patients who have progressed or developed resistance in the second line and beyond. Consolidation immunotherapy following chemoradiation represents the standard approach in locally advanced, unresectable, stage III NSCLC, and ongoing studies are expected to further optimize outcomes in this setting. In resectable disease, neoadjuvant, adjuvant, and perioperative immunotherapy continue to shape an evolving care paradigm, and recent practice-changing advances have transformed curative-intent settings.
This PeerView Live MasterClass educational symposium will provide comprehensive guidance on the evidence-based integration and practical use of current and emerging immunotherapy options. Illustrative case scenarios will be shared to inform clinical decisions and leverage collaboration among care team members to refine the use of immunotherapy along the NSCLC disease continuum. Join us in person or online during #ASCO24 on June 1 at 6:30 PM CDT. https://bit.ly/2024NSCLCL
This activity is supported by independent educational grants from AstraZeneca and Bristol Myers Squibb.
Founder, President ~ LiveLikeCrazy.org 501(c)(3) Breast Cancer Charity
2moPriveleged to be a SFCS Patient/Survivor/ADVOCATE. MyMessage ✔️ CommonThread is the constant advancement ~ progression of Community Care. Managing our treatment "close to home" facilitates our healing.